FAK inhibitors have shown promising anti-tumor immune effects, and combinatorial treatment of FAK and immune checkpoint inhibition is currently being evaluated in a phase I/IIa clinical study across pancreatic cancer, mesothelioma, and NSCLC (NCT02758587)51,55. This evidence concerns the gene PTK2 and neoplasm.